NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $181.33 million versus the consensus estimate of $183.02 million.

GUIDANCE:

NeoGenomics sees FY2025 revenue of $720-726 million, versus the consensus of $744.6 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.